Section Arrow
JSPR.NASDAQ
- Jasper Therapeutics
Quotes are at least 15-min delayed:2026/05/27 15:46 EDT
After Hours
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 0.9099
-0.0027 (-0.30%)
Day High 
0.95635 
Prev. Close
0.9126 
1-M High
1.0299 
Volume 
176.60K 
Bid
0.9005
Ask
0.9184
Day Low
0.8896 
Open
0.9139 
1-M Low
0.7651 
Market Cap 
25.55M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.88 
20-SMA 0.91 
50-SMA 0.95 
52-W High 7.19 
52-W Low 0.623 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.58/-0.87
Enterprise Value
25.55M
Balance Sheet
Book Value Per Share
0.12
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BRTXBioRestorative Therapies0.406999+0.157199+62.93%-- 
After Hours -- -- --
AIMAIM ImmunoTech Inc.0.4038+0.1711+73.53%-- 
After Hours -- -- --
SNGXSoligenix Inc.0.889+0.376+73.29%-- 
After Hours -- -- --
HOTHHoth Therapeutics1.415+0.7067+99.77%-- 
After Hours -- -- --
OTLKOutlook Therapeutics0.5521+0.1519+37.96%-- 
After Hours -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.